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Introduction
The incidence of liver involvement with Hodgkin's disease has
been reported to occur in 5 to 11% of cases at the time of staging
laparotomy (1-4).
At the time of presentation liver involvement is often suspected
on the basis of abnormal physical findings, such as hepatomegaly,
abnormal radiological isotopic scans, or abnormal liver function
tests.

Ultimately confirmation of hepatic disease is dependent

on the more reliable wedge liver biopsy as opposed to percutaneous
needle biopsy.

This is done under direct visualization during

laparotomy.
At Yale from 1969 to 1980, sixteen patients presented with
Hodgkin's disease with liver involvement.

These patients were

all part of a protocol study involving 146 patients with stage 11 IB
and IV Hodgkin's disease.

Of interest was how in particular did

they present clinically; specifically, in terms of basic epidem¬
iology of age, sex, histology and by signs, symptoms and results
of radiological and laboratory tests.

Also of interest is whether

a combination of clinical evidence can be considered reliable
enough to presume liver involvement without laparotomy and wedge
biopsy.
In this study the above clinical parameters were compared with
those presenting in a carefully chosen control group of patients
within the same protocol study who have essentially similar extent
of disease except for biopsy-negative livers.

Materials and Methods
Patients
The members of this study were among 146 patients in a sequential
combination chemotherapy-radiotherapy program in the management
of stage 11 IB and IV advanced Hodgkin's disease.

This study was

conducted at Yale University School of Medicine - Yale-New Haven
Hospital by the Departments of Medicine and Radiotherapy.

It

attempted to define the ability of combination drug therapy to
induce complete remissions and the value of subsequent radiothera¬
py in prolonging remission duration and overall survival.
All patients were staged according to the Ann Arbor Staging
Classification.

Patients considered suitable for combined modal¬

ity therapy were those who were newly diagnosed with stage 11 IB or
IV disease at presentation or those who had relapsed following
initial radical radiotherapy.

Staging procedures included the

usual blood studies, chest x-ray and tomograms, lymphangiograms
and intravenous pyelogram, gallium and

99

technetium liver-spleen

scans, bone marrow aspirate and biopsy, and in some instances liver
biopsy.

Among the relapsed patients, biopsy confirmation of re¬

current disease was required unless there was unequivocal radio¬
logical evidence of Hodgkin's disease.
All patients being treated in this protocol received chemotherapy
first according to the timetable in Figure 1.

Prednisone was given

in a dose of 40mg/square meter for the first 3 weeks of the cycle,
and then tapered off over the next 2 weeks of the cycle. A maxi¬
mum amount of 2.2mg of Vincristine was used.

Drug dosage was re-
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duced depending on the patients' peripheral blood status, degree
of neurotoxicity, and gastrointestinal reaction.
The overall treatment program is schematically represented in
Figure 2.

Three cycles of drugs were given, each cycle lasting

approximately 6 weeks and followed by a 2 week rest interval.
Prednisone was ommitted from the second cycle.

One month fol¬

lowing the completion of the third cycle, remission status was
fully assessed.

A complete remission was defined as the absence

of all clinical, radiographic and laboratory evidence of disease.
Complete responders were then treated with low dose radiotherapy
to the anatomic areas known to have been involved with Hodgkin's
disease before the institution of chemotherapy - with the excep¬
tion of the bone marrow.

Radiation treatments were delivered with

either a 6-MeV or 4-MeV linear accelerator or cobalt - 60 machine.
The doses used were 1,500-2,500 rads at a dose rate of 800-1,000
rads per week.

Patients with hepatic involvement received whole

liver irradiation at rates of 150 rads per treatment with total
dosage not exceeding 2,000 rads.

If more than one radiation field

was necessary and the fields were large, a 2-3 week rest period
between treatments was allowed for bone marrow recovery.
Following radiotherapy, there was a rest period of 3-4 weeks and
then two additional drug cycles were given.
from the fourth cycle.

Prednisone was ommitted

All treatment was stopped at the comple¬

tion of the fifth cycle (14-18 months of total treatment time).
Annual reevaluation included repeat lymphangiograms, appropriate
x-rays, scans and biopsies to access remission status.
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The present study compared two groups of patients within the
aforementioned combined modality therapy protocol.

Group 1 con¬

sisted of 16 patients with biopsy proven liver involvement with
Hodgkin's disease at the time of their presentation with disease.
Group 2 (control group) consisted of 12 patients with stage III
or IV Hodgkin's disease.

All group 2 patients had laparotomies

with biopsy-negative livers.
biopsy-negative spleens.

Five of these patients also had

Tables 1-3 depicts the distribution

of age, sex, and histology among these two groups.
Study Design
The medical records of patients in groups 1 and 2 were reviewed.
A comparison was made between the two groups regarding age, sex, and
histological distribution, evidence of splenic and marrow involvement
at presentation, signs, symptoms, radiological and laboratory
evidence of disease and survival.
Statistical Analysis
Chi-square test was used to determine the significance of dif¬
ferences between proportions.

The Yates' correction was employed

because of the small number of cases studied.

5

★
Figure 1

HODGKIN'S DISEASE
CHEMOTHERAPY PROGRAM

HN 2
0.4 mg /kg i. v.

I

PREDNISONE
40 mg/M2p.o.
VINCRISTINE
1.4 mg/M2 i. v.

i

1

I

VINBLASTINE
6mg/M2 i.v.

I

ui
-j
o
>o
IX
tu

I

PROCARBAZINE
100 mg p.o.
Li
l

j

U

8

15

.

J

.

-22
TIME

1 ,

29

. -..J

36

43

_I

57

(days)

*r

Figure 2
The Overall Treatment Program

3

5

7

9

TIME (months)

* Designed by Alan F. Bloom '83, Yale Medical School

m&mm

mmm*

mmmt

6

Results
Over the past ten years sixteen patients presented to Y-NHH with
biopsy proven liver involvement with Hodgkin's disease.

A study

of their presentation and comparison with a control group is made.
The age distribution of liver patients is 44% under 30 yrs. old
and 56% over 30 yrs. old.

In the control group the distribution

was 66% and 33% respectively (Table 1).

The difference in dis¬

tribution between the two groups isn't statistically significant.
The sex distribution of liver patients is males, 62%; females 38%.
In the control group the distribution is males 58%; females 42%
(Table 2).
The histological distribution of liver patients is nodular
sclerosis, 25%; mixed cellularity, 50%; lymphocyte predominant,
6%; and lymphocyte depleted, 19%.

In the control group the dis¬

tribution was 58%, 33%, 0%, and 9% respectively (Table 3).

The

difference in distribution between the two groups isn't statistically
significant.
The age-histological distribution of liver patients is for
those less than 30 years old-nodular sclerosis 25%; mixed cellu¬
larity 6%; lymphocyte predominant 6%; and lymphocyte depleted 6%.
The respective data for those over 30 are 0%, 44%, 0% and 12%.
Within the control group, the distribution for those less than
30 is, nodular sclerosis 50%; mixed cellularity 17%; and lympho¬
cyte predominant and depleted 0% each.

The respective data for

those over 30 are 8%, 17%, 0% and 8% (Table 4).

Of note is that

the age-histological distribution of liver patients with nodular
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sclerosis and mix cellularity histologies were statistically sig¬
nificant as were the distribution of control patients with lympho¬
cyte predominant histology.

The age-histological distribution

of liver patients over 30 yrs. old with lymphocyte predominant
histology versus a similar control group was statistically sig¬
nificant.

The above were all significant at the 95% confidence

level.
Evidence of splenic involvement at presentation in liver pa¬
tients occurred in 81% of the cases.

This was assessed by biopsy

at laparotomy, abnormal spleen scan or evidence of splenomegaly
by physical exam.

Evidence of marrow involvement, assessed by

aspiration and biopsy, at presentation in liver patients occurred
in 38% of cases.

The respective data among control patients were

50% with splenic involvement and 8% with marrow involvement (Table 5).
The distribution of splenic and marrow involvement in liver pa¬
tients versus controls wasn't statistically significant.

B sym¬

ptoms of weight loss, or fever with or without night sweats were present
in 88% of 1 iver patients at the time of their presentation with
Hodgkin's disease while these symptoms occurred in 67% of the
control patients (Table 6).
shown in Table 5a.

A breakdown of these symptoms is

The difference between these two groups wasn't

statistically significant.
The physical signs at presentation of Hodgkin's disease among
patients with liver involvement and controls is depicted in Tables
7

and 7a.

Hepatomegaly, splenomegaly or both were present in

87% of liver patients as compared with 8% in the controls.

The

difference between these groups was statistically significant (pc.OOOl).
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The radiological evidence of Hodgkin's disease at the time of
presentation is shown in Tables 8, 8a and 8b.

Among the patients

with liver involvement 93% and 92% presented with abnormal liverspleen scans and lymphangiograms respectively.

While only 25% and

75% had abnormal liver-spleen scans or lymphangiograms respectively
among the controls.

Also 69% of the patients with liver involve¬

ment had both abnormal liver-spleen scans and lymphangiograms at
presentation while 6% had abnormal liver-spleen scans with normal
lymphangiograms.
As depicted in Table 8 the difference in distribution of re¬
sults of liver-spleen scans in liver patients and controls is statis¬
tically significant (p<_ .0001) while the difference wasn't statis¬
tically significant regarding the results of lymphangiograms.
Laboratory evidence of disease at presentation is depicted in
Tables 9 and 9a.

Among the patients with liver involvement 94%

had abnormal liver function tests (LFT's), 77% had abnormal albuminglobulin profiles, and 66% had anemia.

In comparison, among the

controls only 33% had abnormal LFT's, 0% had abnormal albumin-glo¬
bulin profiles and 33% had anemia.

The difference between liver

patients and controls was statistically significant regarding LFT's
and albumin-globulin profile (p<_.0001) while the difference re¬
garding anemia wasn't.
In Table 10, is depicted the survival of the patients studied
with liver involvement compared with that of the controls.

Among

the patients with liver involvement 50% are still alive while
100% of the controls are still living.
tically significant (p<_.0001).

This difference is statis¬
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The age distribution of patients with Hodgkin's disease and liver
involvement who has survived without evidence of disease compared
to controls is shown in Table 11.

Those survivors over 30 years

of age among the liver patients versus controls comprise 44% and 100%
respectively.

This difference is not statistically significant.

The survival curve is shown in Figure 3 and detailed in Table 12.
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TABLE 1
AGE DISTRIBUTION OF PATIENTS WITH LIVER
INVOLVEMENT VS. CONTROL

Liver
% of Total

Control
No.
% of Total

Age-Yrs

No.

10-29

7

44%

8

66%

30-59

9

56%

4

33%

16

100%

12

100%

Total

Difference in age distribution between two populations is not statistically
significant.
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TABLE 2
SEX DISTRIBUTION OF PATIENTS WITH LIVER
INVOLVEMENT VS. CONTROLS

Liver
Male
Female
Total

Control

10

62%

7

58%

6

38%

5

42%

16 100%

12

100%
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TABLE 3
HISTOLOGICAL DISTRIBUTION OF PATIENTS WITH
LIVER INVOLVEMENT VS. CONTROLS

Liver
No.
% of Total

Control
No.
/o of Total

Nodular Sclerosis

4

25%

7

58%

Mixed Cellularity

8

50%

4

33%

Lymphocyte Predominant

1

6%

0

0%

Lymphocyte Depleted

3

19%

1

9%

16

100%

12

100%

Total

Difference in histological distribution between two populations is not
statistically significant.
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TABLE 4
AGE-HISTOLOGICAL DISTRIBUTION OF PATIENTS WITH
LIVER INVOLVEMENT VS.

CONTROLS

Liver
10--29 vrs.
No.
% of

Controls
35- 59yrs.
No.
% of

Total

10- 29 yrs.
No.

Total

% of

30- 59yrs.
No.

Total

% of
Total

Nodular Sclerosis

4

25%

0

0%

6

50%

1

8%

Mixed Cellularitv

1

6%

7

44%

2

17%

2

17%

Lymphocyte Predominant

1

6%

0

0%

0

0%

0

0%

Lymphocyte Depleted

1

6%

2

12%

0

0%

1

8%

7

43%

9

56%

8

67%

4

33%

Total

The Age-histologv distribution of NS and MC - hepatic involved pts.

were

statistically significant, as were the age-histology distribution of LPcontrol patients.
The age-histology distribution of LP-HD patients 30-5 9
yrs. old with Hepatic involvement vs. controls were statistically signi¬
ficant.
These were all at the 95% confidence level.
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TABLE 5
EVIDENCE OF SPLENIC OR MARROW INVOLVEMENT
AT ONSET

Control

Liver
No.
w/splenic involvement*
w/o splenic involvement**
Total

w/marrow involvement
w/o marrow involvement
Total

*

8

of the

13 patients with

volvement as well.

% of Total

No.

% of Total

13

81%

6

50%

3

9%

6

50%

16

100%

12

100%

6

38%

1

8%

10

62%

11

92%

16

100%

12

100%

liver involvement had biopsy-proven splenic in¬

The remaining 5 had both abnormal spleen scans and spleno¬

megaly suggesting HD-involvement without biopsy confirmation.
Also all 12
control patients had laporotomies and splenectomies with pathological assessment
of HD-involvement.
case

1 - no pathological,

radiological or clinical data regarding spleen in

medical record.
case 2 - spleen was removed w/o

HD involvement prior to current presentation

in relapse with liver involvement.
case 3 - splenic enlargement noted during exploratory

laporotomy without

pathological specimen of spleen taken.
3

by marrow asp/bx

Distribution of evidence of splenic and marrow involvement in hepatic in¬
volved vs.

control patients wasn't statistically significant.
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TABLE 6
SYMPTOMS AT PRESENTATION

Liver
No.
B symptoms-*w/o B symptoms
Total

wt.

loss,

% of Total

Control
% of Total

No.

14

88%

8

67%

2

12%

4

33%

16

100%

12

100%

fever with or without night sweats.

Distribution of B symptoms

in hepatic involved patients vs.

wasn’t statistically significant.

controls

s
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TABLE 6a
CONSTITUTIONAL SYMPTOMS AT PRESENTATION-DETAILS

Liver

Control

Asymptomatic

1

4

Pruritus Only

1

0

Fatigue

0

0

Weight Loss

3

1

Fever Only

0

0

Fever w/Nite Sweats

1

4

10

3

16

12

Fever w/Nite Sweats & Weight
Loss
Total
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TABLE 7
PHYSICAL SIGNS AT PRESENTATION

Liver_
No.
Adenopathy

% of Total

Control
No.

% of Total

2

12%

11

92%

14

87%

1

8%

16

100%

12

100%

Distribution of physical signs of hepatic involved patients vs.
was statistically significant at the .01% confidence level.

controls

Hepatomegaly,

Splenomegaly

or both
Total
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TABLE 7a
PHYSICAL SIGNS AT PRESENTATION-DETAILS

Liver

Control

Peripheral Adenopathy Only

2

11

Hepatomegaly

2

0

Splenomegaly

4

1

Hepatosplenomegaly

8

0

16

12

Total
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TABLE 8
RADIOLOGICAL EVIDENCE OF DISEASE AT PRESENTATION

Controls

Liver
No.
Normal Liver-Spleen Scans
Abnormal Liver-Spleen Scans
Total
Normal LAG
Abnormal LAG
Total

% of Total

No.

% of Totals

1

7%

6

75%

13

93%

2

25%

14

100%

8

100%

1

8%

3

25%

12

92%

9

75%

13

100%

12

100%

Distribution of L/S scan results of hepatic involved patients vs.
trols was statistically significant at the
results of LAG's was not.

con¬

.01% confidence level, while
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TABLE 8a
LIVER-SPLEEN SCANS IN PATIENTS WITH LIVER
INVOLVEMENT VS.

CONTROLS

Liver
No.

% of Total

Controls
No.

Normal L/S Scan

1

6

ILiver w/o Focal Defects

2*

0

ILiver w/ Focal Defects

0

0

ISpleen w/o Focal Defects

0

2

iSpleen w/ Focal Defects

A

0

+L/S w/o Focal Defects

3

0

1L/S w/ Focal Defects

A

0

1A

8

Total

*

1 patient had splenectomy prior to presentation with
1 patient had a normal spleen scan.

% of Total

liver involvement.
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TABLE 8b
COMPARISON OF LIVER/SPLEEN SCANS W/LYMPHANGIOGRAM

Liver
No.

% of Total

Control
No.
% of Total

Both abnormal L/S scan and
Lymphangiogram

11

69%

2

16%

Abnormal L/S Scan w/normal

1

6%

0

0%

1

6%

5

42%

Both normal L/S scan and
Lymphangiogram

0

0%

0

0%

Without L/S scan or LAG

3

19%

5

42%

16

100%

12

100%

LAG
Normal L/S scan w/abnormal
LAG

Total
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TABLE 9
LABORATORY EVIDENCE OF DISEASE AT PRESENTATION

Control

Liver
No.

% of Total

No.

% of Total

1

6%

10

67%

15

94%

2

33%

16

100%

12

100%

2

23%

4

100%

7

77%

0

0%

9

100%

4

100%

Anemia

8

67%

4

33%

w/o anemia

4

33%

8

67%

12

100%

12

100%

Normal LFT's
Abnormal LFT's
Total
Normal Albumin/Globulin
Profile
Abnormal Albumin/Globulin
Profile
Total

Total

Distribution of LFT’s and A/G in hepatic involved pts.

vs.

controls were

statistically significant the 99.99% confidence level, while distribution
of anemia wasn't significant.
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TABLE 9a
LABORATORY VALUES OF PATIENTS WITH LIVER INVOLVEMENT

Liver

Serum

Function

Protein

Complete
Blood Count

Tests

Electrophoresis

With Differential

E. A.

iLDH

N.I.

Normal

A. B.

tSerum Cu

N.I.

Hvpochronic,Microcytic Anemia,
Granulocytosis,Monocytosis,Lym¬
phopenia

P.R.

tLDH,PT,PTT,CT
Thymol Turbidity

G.I.

A4-G1; inonspecif ic
“ globulin

tCephlatin Flocculation A4-GL

Normochronic,Normocytic Anemia

Thymol Turbidity
R.W.

ILDH,Aik Phos,SGOT,

Normochronic,Normocytic Anemia
Granulocytosis,Lymphopenia

Neutropenia,Lymphocytosis
AIG1

f^jglobulin

Bilirubin,5'Noc,Cu
PT,Thymol Turbidity

Normochronic,Normocytic Anemia
Neutropenia,Lymphopenia,Trombocytopenia,Monocytosis

R.K.

Normal

Normal

Normal

J.W.

ISerum Cu

A1G+ lcc2gl°t,ulin

Normal

M.D.

"abnormal LFT's"

N.I.

N.I.

F.L.

+Aik Phos,LDH,SGOT,
PT

AlGt

Normochronic,Normocytic Anemia
Granulocytosis,Lymphopenia

C.D.

fBSP,Aik Phos,Bilirubin AlGi

Hypochronic,Microcytic Anemia
Granulocytosis,Lymphopenia

J.M.

+Alk Phos,SGOT,PT,PTT,
BSP

Normal

Anemia w/o

J.B.

"abnormal LFT’s"

N.I.

N.I.

L.R.

"abnormal LFT's"

N.I.

N.I.

P.F.

"abnormal LFT's"

A1G1

S.O.

1BSP

N.I.

Granulocytosis,Lymphocytosis

M.S.

lAlk Phos.

N.I.

N.I.

N.I.- No information

Indices Neutropenia

Lymphocytosis

f^globulin

Hypochronic Microcytic Anemia
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TABLE 10
SURVIVAL

Liver
No .

% of '

50%

12

100%

8

50%

0

0%

16

100%

12

100%

2

Total

No.

8

Alive *
Deceased

Control

% of Total

Distribution of survival of hepatic involved patients vs.
significant at the 99.99% confidence level.
^

with no evidence of Hodgkin’s disease.

^

died with Hodgkin’s disease.

controls was statistically
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TABLE 11
AGE DISTRIBUTION OF PATIENTS WITH LIVER
INVOLVEMENT WHO HAS SURVIVED VS.

CONTROLS

Liver
No.

% Alive

Control
No.

% Alive

10-29

4

57%

8

100%

30-59

4

44%

4

100%

Total

16

The distribution between patients with liver involvement vs.
statistically significant.

12

controls

is not
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FIGURE 3
Survival Curve of Patients with Liver Involvement
Response
None
Partial
Complete

100
75
1o

Surviving
50
4

- ^—,-—

1

r-

.—

5
7.5
years
since diagnosed

10

No.
3
5
8

A1 ive
0
1
7
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TABLE

12

Survival Data

Years Followup

No.

0-1

5

(all DWD*)

Response

to Chemotherapy

3- No Response
2- Partial Response

3

1-5

2- Partial Response - both DWD
1- Complete Response
(diagnosed <5 years ago;

still

alive)
5-10

4

3- Complete Response -

1 DWD

(1 with radiation Tx failure
mediastinum;

to

still alive)

1- Partial Response
(with radiation Tx failure in Rt
axilla;
10

4
Total

*DWD - dead

16

with disease

still alive)

4- Complete Response
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DISCUSSION
The present study attempts to review the presentation of advanced
Hodgkin's disease patients with liver involvement.
Liver involvement with Hodgkin's disease showed no particular age
predilection being approximately equally distributed above and below
30 yrs. of age.

Studies of age-specific incidence of Hodgkin's

disease by MacMahon (5) and, in particular, in Connecticut by Correa
and O'Conor (6) suggest a bimodal distribution of approximately
equal magnitude centering around 40 yrs.

This suggests that pa¬

tients presenting with Hodgkin's disease and liver involvement
have similar age-specific incidences as Hodgkin's disease in general.
Hodgkin's disease is more prevalent in males than in females.
A male-female sex ratio ranging from 1.38 to 1.94 has been cited;
not changing appreciably from data as far back as 1911 (7).
Patients with liver involvement in our study revealed a similar
predominance with a male-female sex ratio

of 1.63 compared to

the control groups ratio of 1.38.
The histological breakdown of Hodgkin's disease has been var¬
iously reported as nodular sclerosis approximately 50%; mixed cellularity about 40% and lymphocyte predominant and depleted each
about 5% respectively.

The distribution among our liver patients

is distinct but the number in our study is too small to draw sta¬
tistically significant inference in comparison to the general populationof Hodgkin's cases.

Nevertheless, it is of interest to

note that among our patients with liver

involvement, the most

common histopathologies were mixed cellularity and nodular sclerosis
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and the least common was lymphocyte predominant.

This would be pre¬

dicted based on studies by Kadin, Glatstein and Dorfman

(8) and

Dorfman (9) who showed that the predominance of patients with para¬
aortic and splenic

involvement had histologic diagnosis which were

most commonly mixed cellularity and nodular sclerosis.

Furthermore

the predominance of clinical stage III and IV were among those
patients with mixed cellularity and nodular sclerosis as histologic
diagnosis while most patients with stage I were confined to lym¬
phocyte predominant cases.

In addition, vascular invasion of the

spleen was shown by Kirschner et.al. (10) to be important in wide¬
spread dessemination.

In his study he showed that vascular invasion

in 16% of 44 spleens examined at laparotomy were associated with
dissemination to the liver and bone marrow.

In Rappaport and

Strum's study (11) the percentage incidence of vascular invasion
per histological type was found to be lymphocyte depleted 43%,
mixed cellularity 3%, nodular sclerosis 8%, and lymphocyte pre¬
dominant 0%.

If one were to consider the prevalence of each his¬

tological type of Hodgkin's disease in the general population and
multiply it by the % incidence of vascular invasion per each his¬
tological type as estimated by Rappaport and Strum one may get a
distribution of histological types in patients with liver involve¬
ment which might approximate our results in Table 3.
The age-histological distribution of patients with liver involve¬
ment and histologies of either nodular sclerosis or mixed cellularity
was statistically significant as is shown in Table 4.

Patients with

nodular sclerosis were predominantly under 30 and those with mixed
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cellularity were over 30.

This is in general agreement with the age-

histological distribution of Hodgkin's patients studied by Keller
et.al. (12) which revealed a peak in the 15 to 25 year age range
for nodular sclerosis, whereas the peak for mixed cellularity appears
to occur distinctly later between 25 and 45 years of age.

This sug¬

gests that for those Hodgkin's disease patients presenting with
liver involvement and with histologies of mixed cellularity or
nodular sclerosis their age distribution were no different than those
of Hodgkin's disease patient in general.
It is generally held that Hodgkin's disease progresses via con¬
tiguous spread of lymphatic chains.

The spleen is involved via lym¬

phatic spread and within the spleen vascular invasion occurs and it
is by the blood that the liver subsequently becomes involved.

In

over 800 diagnostic laparotomies reviewed by Kaplan there has been
no instance of liver involvement without concomitant splenic in¬
volvement.

This is supported by our data in Table 5.

Therefore it

was questioned whether clinical evidence of splenic involvement would
be fairly reliable evidence of liver involvement as well.

As can be

appreciated by Table 5, although a preponderance of patients with liver
involvement presented with clinical evidence of splenic involvement,
50% of the control patients presented with clinical evidence of splenic
involvement as well either by biopsy, abnormal spleen scan and/or
evidence of splenomegaly on exam. Also the difference in distribution
between the liver group and controls were statistically insignificant,
since there is no difference in the likelihood of having clinical
evidence of splenic involvement in either biopsy proven liver

Therefore,
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patients or controls one can not use this as a criteria for orobable
hepatic involvement.
The bone marrow is involved with Hodgkin's disease in from 5-15%
of previously untreated patients (13).
with stage III or IV disease.

It is generally associated

Invariably the spleen is also involved.

Again because of the suspected close association of splenic and
hepatic involvement it was questioned what would be the association
between marrow and liver involvement.

As shown in Table 5, the

marrow was found to be involved in the minority of cases in both
the liver patients and controls, the distribution between the
two groups being statistically insignificant.

Therefore evidence

of marrow involvement cannot be used as strong suggestive evidence
of hepatic involvement.
It is well established that constitutional symptoms are re¬
latively infrequent in stage I cases, predominating in stages III
and IV.

Therefore it was questioned if compared to our control

group of stage III and IV patients with negative liver biopsies,
whether patients with liver involvement presented more frequently
with B symptoms of fever, weight loss, or night sweats.

As shown

in Tables 6 and 6a, the majority of patients in both the study and
control groups presented with B symptoms; the difference not being
statistically significant.

Consequently it appears that consti¬

tutional symptoms is more a function of anatomical extent of disease
in general.
Therefore the presence of B symptoms in patients with advanced
Hodgkin's disease isn't a specific marker for liver involvement.
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Nevertheless, it is worth noting that 10 patients with liver in¬
volvement presented with all 3 B symptoms while only three pa¬
tients among the control group presented in such a manner.

Also

4 patients in the control group presented asymptomatically versus
only one in the study group.

This suggests that generally patients

presenting with liver involvement will most likely have more im¬
pressive constitutional symptoms at presentation including quite
frequently weight loss, fever, and night sweats simultaneously.
Of particular interest are the physical signs at presentation of
patients with liver involvement compared to controls.

The major¬

ity of patients with liver involvement oresented with hepatomegaly,
splenomegaly or both (87%) compared to only one patient with
splenomegaly in the control group (8%).

Also 92% of patients in

the control group presented with peripheral adenopathy only com¬
pared with 12% among the patients with liver involvement.
differences were statistically significant (p<_.0001).

These

Of interest

is that no patients in the control group presented with either hepa¬
tomegaly or hepatosplenomegaly while 12% and 50% respectively
presented with these signs among the patients with liver involvement.
Therefore these two signs appear to be fairly reliable indicators
of liver involvement.
Liver-spleen scans have been investigated for sometime as diag¬
nostic adjuncts in the clinical staging of Hodgkin's disease.
Lipton et.al. (14) reviewed 49 liver scans but only four cases
had biopsy proven liver involvement thus limiting the reliability
of conclusions drawn from that study despite the fact that all four
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cases had abnormal liver scans.

Milder et.al.

(15) reviewed the

liver-spleen scans in 108 patients with Hodgkin's disease.

Only

20 patients in this study had biopsy proven liver involvement.

Of

these patients, only 10 demonstrated filling defects or mottled
uptake on scan.

It is presumed that the others were normal al¬

though no information was given as to the size of the liver.
defects were also present in 25% of biopsy negative livers.

These
Con¬

sequently, except for the size of the left lobe, no finding on
liver scan was concluded to be diagnostic of tumor involvement.
Although the authors suggest that a combination of results from
lymphangiogram liver-spleen scans, and physical exam may be used
to form an index of suspicion for liver involvement which may
prove useful in avoiding laparotomy, they concluded for the present,
as did Lipton et.al., that only histiological examination of ade¬
quate liver biopsies can be considered definitive evaluation for
liver involvement.
The result of our study of liver-spleen scans suggests that
they may be more useful in the diagnostic workup of liver involve¬
ment than previously indicated.

Specifically as indicated in Tables

8 and 8a, 93% of patients with biopsy-positive liver involvement
presented with abnormal liver-spleen scans whereas only 25% in the
control group presented with abnormalities.
statistically significant.

This difference is

Of note is that of the two control pa¬

tients with abnormal liver spleen scans both had only enlarged
spleens without focal defects.

This finding has been commonly

attributed to reactive hyperplasia secondary to Hodgkin's disease
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elsewhere.

Also every patient with liver involvement who presented

with an abnormal liver-spleen scan - except for one - had at least
an abnormal spleen scan.

This again; albeit in a rather crude

fashion gives further support that splenic involvement always preceeds liver involvement.
Among the patients with liver involvement, 92% presented with
abnormal lymphangiograms while 8°l viere normal.

Considering the

contiguous spread of Hodgkin's disease from nodes to spleen and
than liver, one can assume that the 8% is a false negative rate
which is much higher than the 2% false negative rate which is
usually quoted for lymphangiograms (16).
A number of investigators have attempted to find some cor¬
relation between liver function tests and liver involvement with
Hodgkin's disease.

Glatstein et.al.

(17) reviewed the liver func¬

tion tests of 29 patients with suspected or biopsy-proven liver
involvement, they concluded that involvement was not well cor¬
related with anyone liver function test.

Although abnormalities

of each liver function test could be demonstrated at one time or
the other among the several cases, BSP retention and alkaline phos¬
phatase tended to be abnormal more frequently.

Of the 12 patients

who had both BSP retention and alkaline phosphatase abnormalities
only 7 had positive liver biopsies the remainder were biopsy ne¬
gative.
Aisenberg et.al.

(18) studied the serum alkaline phosphatase

levels in 111 patients at the onset of Hodgkin's disease.

He found

that with increasing stages of the disease, there was an increasing
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percentage of patients with

elevated levels of enzymes, for example,

14% in stage I and 81% in stage IV.

Electrophoretic studies of the

phosphatase revealed that most of the elevated levels were hepatic
in origin and that this was the source in virtually all of the
advanced cases.

But the association of elevations in stage I cases,

in cases with negative liver biopsies and being reversible associated
with fevers, all imply the unreliability of elevated alkaline phos¬
phatase as a specific marker of hepatic involvement.

The conclusions

of Aisenberg et.al. were later supported by the work of Belliveau
et.al.

(19) and with the increasing suggestion of non-neoplastic

hepatic disease presenting concomitantly with Hodgkin's disease
(20,21) all raised serious questions as to the utility of liver
function tests for diagnosis of liver involvement.
More support for the use of liver function tests can be found
in the result of our study.

Of the 16 patients with biopsy-proven

liver involvement only one patient presented with normal liver
function tests.

As shown in Tables 9 and 9a among the patients

with liver involvement, 94% presented with abnormal LFT's while
only 33% of the control patients had abnormal LFT's.

This dif¬

ference was highly statistically significant (p<_.0001).
9a reveals the wide variety of abnormalities in LFT's.

Table
Of note

is that elevated alkaline phosphatase was the most common ab¬
normality and that in several cases only one test was positive.
This suggests the necessity to use a wide variety LFT's to detect
potential liver involvement.
Serum protein abnormalities have been well described in Hodgkin's

t
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disease.

Arends et.al.

(22) and Neely et.al.

(23) have demonstrated

that in Hodgkin's disease, hypoalbuminemia and increased concen¬
trations of alpha^, alpha2, and/or beta globulins occurred commonly.
Also the instances of hypergama-globulinemia was not associated
with overt evidence of hepatic involvement, infection or increased
numbers of plasma cells in bone marrow.

Waldmann et.al.

albumin metabolism in patients with lymphoma.

(24) studied

His evidence con¬

curred with that of others (25) suggesting that hypoalbuminemia
was secondary to diminished albumin synthesis.

Deficient caloric

intake, malabsorption, liver damage, nitrogen trapping by the
tumor have all been speculated as causes of the protein abnormalities.
But in many of the patients studied these abnormalities couldn't
fully explain the deficiency seen nor has anyone to date been able
to adequately explain the specific etiology of the serum protein
abnormalities.
No one has ever specifically investigated serum protein ab¬
normalities in patients with documented biopsy-proven liver in¬
volvement with Hodgkin's disease.

In this study 78% of patients

with liver involvement had hypoalbuminemia and hyperglobulinemai.
Some patients demonstrated elevated levels of alpha^, alpha2 or
gammaglobulin.
malities.

No patients among the control had protein abnor¬

This difference is statistically significant.

trol patients had approximately as extensive tumor loads.

The con¬
Thus

negating factors dependent on this as causes of protein abnormal-ities, for example, nitrogen trapping, severe systemic symptoms, and
decreased caloric input.

This data suggests that perhaps liver
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disease may be the cause of serum protein abnormalities in the
majority of instances of Hodgkin's disease.

There is no instance

of serum protein abnormality without positive liver function tests
although the inverse is true.

Consequently, protein profiles don't

seem to be a more sensitive indicator of liver involvement than
routine LFT's.

On the other hand in comparison with the results

of LFT's among controls, protein profiles may be a more specific
indicator of liver involvement.
Anemia is the most serious initial hemotological abnormality
found among Hodgkin's patients.
phases of advanced disease.

It usually occurs during the later

As shown in Tables 9 and 9a, anemia

was present in 66% of patients with liver involvement at presen¬
tation while 33% of control patients viere anemic.
was not statistically significant.

This difference

Among patients with liver in¬

volvement three had a hypochronic, microcytic anemia while five
had a normochronic,normocytic anemia.

In no patients were there

evidence of blood loss, or a hemolytic process.

Although the

cause of the anemias were not made clear by this study, it appears
that liver involvement doesn't add significantly to the incidence
of anemia in Hodgkin's disease. Rather the anemias are probably
secondary to advanced disease.

The hypochronic, microcytic anemias

were probably secondary to chronic disease.

Since four of five

patients with liver involvement and normochronic, normocytic anemias
also had positive bone marrow biopsies, it is speculated that perhaps
the cause of this anemia is bone marrow invasion with neoplasia.
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One would suspect that patients with liver involvement might do
poorly secondary to major organ disease.

As shown in Tables 10 and

11, half of the patients in the study group died of their disease
while none of the control patients demised.
statistically significant (p<_.0001).

This difference is

As Table 11 indicates age

doesn't appear to have a significant effect on survival.

Referring

to the survival curve (Figure 3) and Table 12 it is worth noting
that of the five liver patients that died within one year after their
diagnosis, three achieved no response from chemotherapy and the re¬
maining two achieved only partial remission.
radiation and all died with this disease.

None were salvaged by

Of the remaining three

patients that survived between one and five years after their diag¬
nosis, two had only partial responses to chemotherapy and also died
with their disease.

The remaining patient had a complete response

to chemotherapy and is currently alive without evidence of Hodgkin's
disease.
Of the four patients in the combined modality Yale protocol with
liver involvement who have survived ten years or greater without evi¬
dence of Hodgkin's disease, all had complete responses to chemotherapy
initially.

None had irradiation site failures except one who had a

relapse in the mediastinum which responded to cycles 4 and 5 of chemo¬
therapy.
Regarding age, sex, histology, and general state of health prior
to diagnosis there didn't appear to be anything distinctive among
liver patients who died or are currently alive without evidence of
disease.
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